(Liver Cancer) Is Tecentriq + Avastin Effective?

On October 21, 2019, Roche announced the efficacy and safety results from the IMbrave150 Phase III clinical trial evaluating the anti-PD-L1 antibody Tecentriq (atezolizumab) + Avastin (bevacizumab) in previously untreated, unresectable hepatocellular carcinoma (HCC) patients.

The IMbrave150 Phase III trial was a multicenter international open-label study. Previously untreated, unresectable HCC patients (N=501) were randomized in a 2:1 ratio to the following two groups:

• Tecentriq + Avastin group: Tecentriq 1200 mg + Avastin 15 mg/kg on Day 1 of each 21-day cycle
• Sorafenib (Nexavar) 400 mg monotherapy group

Results for the primary endpoints — overall survival (OS) and progression-free survival (PFS) — both demonstrated improvements in the Tecentriq + Avastin group. Detailed trial results are to be presented at a future academic conference. In terms of safety, the adverse events observed with Tecentriq in this trial were consistent with the profiles confirmed in other ongoing clinical trials, with no new adverse events identified.

Based on the IMbrave150 trial results, Levi Garraway issued the following conclusion: For previously untreated, unresectable HCC patients — where sorafenib monotherapy is the current standard of care — Tecentriq + Avastin demonstrated improved overall survival, which is a reason for optimism.

Source: https://www.roche.com/media/releases/med-cor-2019-10-21.htm

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Related Cancer Information

• Liver cancer